目的：探讨动态增强磁共振（DCE-MRI）扫描定量参数测定对鉴别肺部肿块良恶性的可行性。方法：77例肺部肿块患者行3.0T MR动态增强扫描，并经手术或穿刺活检病理证实，测量定量参数：容量转移常数（Ktrans）、速率常数（Kep）和血管外细胞外间隙容积比（ve），分别对良性病变、恶性病变定量参数值进行统计学分析；最后绘制ROC曲线。结果：恶性病变组：低分化腺癌Ktrans、Kep、ve均值分别为（0.270±0.089） min-1、（0.926±0.475） min-1、0.340±0.144，低分化鳞癌分别为（0.268±0.066） min-1、（0.997±0.464） min-1、0.293±0.091，小细胞癌均值为（0.238±0.074） min-1、（0.617±0.369） min-1、0.412±0.312；良性病变组Ktrans、Kep、ve均值分别为（0.190±0.084） min-1、（0.569±0271） min-1、0.392±0.207。良、组行独立样本t检验，Ktrans、Kep值均有统计学差异（P值均<0.05），ve值无统计学差异（P值＞0.05），良性病灶组分别与低分化腺癌、低分化鳞癌组行成组设计方差分析， Ktrans及Kep差异均有统计学意义（P值均＜0.05），ve均无统计学差异（P值均＞0.05）；低分化腺癌与低分化鳞癌Ktrans、Kep、ve差异均无统计学意义（P值均＞0.05）。良性病灶组及恶性病灶组ROC曲线下面积分别为0.741、0.715，敏感性分别为88.4％、39.5％；特异性分别为54.2％、95.8％。结论：DCE-MRI定量参数Ktrans、Kep值鉴别诊断肺部肿块具有可行性，有助于对肺癌及肺部良性病灶进行鉴别。
Abstract
Objective: To investigate the feasibility of quantitative analysis parameters of dynamic contrast-enhanced MRI (DCE-MRI) in diagnosis of lung neoplasms and assess the differences of quantitative MR pharmacokinetic parameters volume transfer constant(Ktrans), exchange rate constant(Kep) and extravascular extracellular volume fraction(ve) in lung neoplasms. Methods: Three Tesla MR examinations were performed in 77 patients confirmed by biopsy and the quantitative MR pharmaeokinetic parameters including Ktrans, Kep and ve were obtained. Independent two sample t test was used between benign and malignant lung lesions. Finally, the areas under the ROC curve(AUC) of Ktrans, Kep and ve between malignant and benign lesions were compared. Results: The mean Ktrans, Kep and ve of poorly differentiated adenocarcinoma(n=26) were(0.270±0.089) min-1, (0.926±0.475) min-1 and (0.340±0.144). The mean Ktrans, Kep and ve of poorly differentiated squamous cell carcinoma(n=13) were (0.268±0.066) min-1, (0.997±0.464) min-1 and (0.293±0.091). The mean Ktrans, Kep and ve of small-cell lung cancer were (0.238±0.074) min-1, (0.617±0.369) min-1 and (0.412±0.312). The mean Ktrans, Kep and ve of benign lesions(n=24) were (0.190±0.084) min-1, (0.569±0.271) min-1 and (0.392±0.207). There was significant difference between malignant and benign lesions in either Ktrans or Kep(t=3.697, 3.883, respectively, P<0.05). There was no significant difference between malignant and benign lesions in ve(t=1.341, P＞0.05). Ktrans and Kep values of benign lesions were significantly lower than those of squamous cell carcinoma and adenocarcinoma(both P＜0.05). No significant difference was observed between squamous cell carcinoma and adenocarcinoma in Ktrans or Kep(both P＞0.05). The AUCs of Ktrans and Kep between malignant and benign lesions were 0.741 and 0.715. The sensitivity of Ktrans and Kep were 88.4％ and 39.5％, and the specificity of Ktrans and Kep were 54.2％ and 95.8％. Conclusion: The differential diagnosis of benign and malignant lung lesions by Ktrans and Kep is applicable.
关键词
肺肿瘤 /
活组织检查 /
针吸 /
磁共振成像
Key words
Lung neoplasms /
Biopsy, needle /
Magnetic resonance imaging
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Westerhof JP, Fischer U, Moritz JD, et al. MR imaging of mammographically detected clustered microcalcifications: is there any value?[J]. Radiology, 1998, 207(3): 675-681.
[2]Ohno Y, Hatabu H, Takenaka D, et al. Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience[J]. Radiology, 2002, 224(2): 503-511.
[3]Schaefer JF, Vollmar J, Schick F, et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions[J]. Radiology, 2004, 232(2): 544-553.
[4]Tofts PS, Brix G, Buckley DL. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols[J]. J Magn Reson Imaging, 1999, 10(3): 223-232.
[5]Choyke PL, Dwyer AJ, Knopp MV, et al. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging[J]. J Magn Reson Imaging, 2003, 17(5): 509-520.
[6]Baek HM, Yu HJ, Chen JH, et al. Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer[J]. Magn Reson Imaging, 2008, 26(4): 523-531.
[7]李春媚，陈敏，李飒英，等. 3.0T MR动态增强扫描定量分析诊断前列腺癌的初步研究[J]. 中华放射学杂志，2011，45（1）：50-54.
[8]Hou Z, Wang Y, Thng CH, et al. Automatic region-of-interest segmentation and registration of dynamic contrast-enhanced images of colorectal tumors[J]. Phys Med Biol, 2014, 59(23): 7361-7381.
[9]Geith T, Biffar A, Schmidt G, et al. Quantitative analysis of acute benign and malignant vertebral body fractures using dynamic contrast-enhanced MRI[J]. AJR, 2013, 200(6): 635-643.
[10]Port RE, Knopp MV, Hoffmann U, et al. Multi-compartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging[J]. J Magn Reson Imaging, 1999, 10(3): 233-241.
[11]Yu CW, Shih TT, Hsu CY, et al. Correlation between pancreatic microcirculation and type 2 diabetes in patients with coronary artery disease: dynamic contrast-enhanced MR imaging[J]. Radiology, 2009, 252(3): 704-711.
[12]Amarnath J, Sangeeta T, Mehta SB. Role of quantitative pharmacokinetic parameter(transfer constant: Ktrans) in the characterization of breast lesions on MRI[J]. Ind J Radiol Imaging, 2013, 23(1): 19-25.
[13]Vos EK, Litjens GJ, Kobus T, et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3T[J]. Eur Urol, 2013, 64(3): 448-455.
[14]Barrett T, Brechbiel M, Bemardo M, et al. MRI of tumor angiogenesis[J]. J Magn Reson Imaging, 2007, 26(2): 235-249.
[15]Baik SH, Jin GY, Han YM, et al. Usefulness of tissue permeability factor in differentiating benign and malignant pulmonary lesions on dynamic contrast-enhanced MRI[J]. J Kor Soc Radiol, 2013, 69(1): 57-65.
[16]Ng CS, Raunig DL, Jackson EF, et al. Reproducibility of perfusion parameters in dynamic contrast enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses[J]. AJR, 2010, 194(2): 134-140.
[17]Langer DL, der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2 diflusion-weighted imaging, and dynamic contrast-enhanced MRI[J]. J Magn Reson Imaging, 2009, 30(2): 327-334.
[18]Tofs PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging[J]. J Magn Reson Imaging, 1997, 7(1): 91-101.
[19]Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue[J]. Invest Radiol, 2009, 44(9): 577-584.
[20]Wang Y, Huang W, Panicek DM. Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data[J]. Magn Reson Med, 2008, 59(5): 83-89.
[21]Kono R, Fujimoto K, Terasaki H, et al. Dynamic MRI of solitary pulmonary nodules: comparison of enhancement patterns of malignant and benign small peripheral lung lesions[J]. AJR, 2007, 188(1): 26-36.
